Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin and Antiviral Treatment in Liver Cancer After Radical Surgery
NCT01936233Phase 3Unknown
- Sponsor
- Fudan University
- Start
- Aug 2013
- Primary completion
- Dec 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised trial of aspirin in hepatocellular carcinoma (HCC) (2 arms), sponsored by Fudan University. Primary endpoint: Recurrence Free Survival at 36 months. Status: unknown.
02
Drugs
aspirin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01936233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01936233.